Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F, Mazza P, Carella AM, Mele A, Palazzo G, Pisapia G, Carluccio P, Pastore D, Cascavilla N, Specchia G, Pavone V. Gaudio F, et al. Among authors: pavone v. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40. doi: 10.1016/j.clml.2018.08.012. Epub 2018 Sep 12. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30293754
Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).
Delia M, Carluccio P, Buquicchio C, Vergine C, Greco G, Amurri B, Melpignano A, Melillo L, Cascavilla N, Guarini A, Capalbo S, Tarantini G, Mazza P, Pavone V, Di Renzo N, Specchia G. Delia M, et al. Among authors: pavone v. Leuk Res. 2015 Aug 20:S0145-2126(15)30358-1. doi: 10.1016/j.leukres.2015.08.005. Online ahead of print. Leuk Res. 2015. PMID: 26364798
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S. Pavone V, et al. Ann Hematol. 2018 Oct;97(10):1817-1824. doi: 10.1007/s00277-018-3379-5. Epub 2018 Jul 27. Ann Hematol. 2018. PMID: 30054707
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Mele G, Pastore D, Di Renzo N, Fragasso A, Guarini A, Mazza P, Musto P, Pavone V, Tarantini G, Curci P, Falcone AP, Mele A, Miccolis MR, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rizzi R, Cascavilla N, Specchia G, Capalbo SF. Mele G, et al. Among authors: pavone v. Leuk Lymphoma. 2019 Dec;60(14):3565-3568. doi: 10.1080/10428194.2019.1636989. Epub 2019 Jul 9. Leuk Lymphoma. 2019. PMID: 31286780 No abstract available.
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N. Mele G, et al. Among authors: pavone v. Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23. Leuk Res. 2015. PMID: 25636354
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Musso M, et al. Among authors: pavone v. Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
Di Renzo N, Melillo L, Porretto F, Dargenio M, Pavone V, Pastore D, Mazza P, Mannina D, Merenda A, Cascavilla N, Greco G, Matera R, Bonizzoni E, Celio L, Musso M. Di Renzo N, et al. Among authors: pavone v. Cancer Med. 2020 Jan;9(1):170-178. doi: 10.1002/cam4.2628. Epub 2019 Nov 14. Cancer Med. 2020. PMID: 31725196 Free PMC article. Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A, Prete E, De Risi C, Citiso S, Greco G, Falcone AP, Sanpaolo G, Mele G, Giannotta A, Vergine C, Reddiconto G, Palazzo G, Sabatelli S, Germano C, Miccolis R, Curci P, Palumbo G, Offidani M, Rizzi R, Cascavilla N, Pastore D, Di Renzo N, Mazza P, Tarantini G, Guarini A, Capalbo S, Specchia G, Greco A, De Francesco R, Sibilla S, Tonialini L, Morciano MR, Pavone V. Mele A, et al. Among authors: pavone v. Ann Hematol. 2021 Feb;100(2):429-436. doi: 10.1007/s00277-020-04329-3. Epub 2020 Nov 7. Ann Hematol. 2021. PMID: 33161453
448 results